<DOC>
	<DOCNO>NCT01114880</DOCNO>
	<brief_summary>Study efficacy safety adalimumab compare placebo adult Chinese participant ankylose spondylitis ( AS ) inadequate response intolerant one nonsteroidal anti-inflammatory drug ( NSAIDs )</brief_summary>
	<brief_title>Efficacy Safety Adalimumab Adult Chinese Subjects With Active Ankylosing Spondylitis</brief_title>
	<detailed_description>Adults active ankylose spondylitis ( AS ) randomize 2:1 ratio receive treatment adalimumab 40 mg every week ( eow ) match placebo , give subcutaneously ( SC ) , 12-week double-blind ( DB ) phase . Randomized participant receive one SC injection appropriate DB study medication ( adalimumab 40 mg match placebo ) Week 0 eow Week 10 . Participants complete DB phase could enter 12-week open-label ( OL ) phase , participant receive treatment adalimumab 40 mg eow , start Weeks 12 22 . No study drug administer inject final study visit ( Week 24 ) . A follow-up visit occur 70 day last dose study drug ( DB OL phase ) obtain information ongoing new adverse event ( AEs ) .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Age 18 65 year Has diagnosis ankylose spondylitis ( AS ) base Modified New York Criteria Has active AS , define fulfillment least 2 follow 3 condition Screening Baseline visit : BASDAI score least 4 cm Total back pain visual analog scale ( VAS ) least 40 mm Morning stiffness least 1 hr Has inadequate response intolerance one nonsteroidal antiinflammatory drug ( NSAIDs ) define Investigator Has total spinal ankylosis ( bamboo spine ) Has undergone spinal surgery joint surgery involve joint assess within 2 month prior Baseline Has extraarticular manifestation ( i.e. , psoriasis , uveitis , inflammatory bowel disease ) clinically stable , define Investigator 's best clinical judgment , least 28 day prior Baseline Has receive intraarticular joint injection ( ) , spinal paraspinal injection ( ) corticosteroid within 28 day prior Baseline Has prior exposure biologic therapy potential therapeutic impact AS , include antiTNF ( tumor necrosis factor ) therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>ankylose spondylitis</keyword>
	<keyword>China</keyword>
</DOC>